RSP initiates an extensive clinical study in collaboration with Odense University Hospital. The Hospital is a leading partner within the diabetes care and research field. This study involves 72 diabetics, and runs until Q4 2016. Purpose of the study is to demonstrate the accuracy of RSP Systems’ 3rd generation prototype of the GlucoBeam®. GlucoBeam® is a non-invasive glucose monitor based on the company’s proprietary and patented optical Raman technology.
New clinical study
The new study builds on earlier clinical studies that have demonstrated the capability of the GlucoBeam® to measure glucose non-invasively. With its new 3rd generation prototype, the company expects to demonstrate a strongly improved glucose measuring performance. Furthermore, it will show an accuracy sufficient for a commercial glucose monitoring device. RSP’s Chief Technology Officer, Stefan O. Banke, says: “We are excited about the progress obtained in the course of the last two years of development. Our devices are now capable of selectively collecting the optical glucose signal from the appropriate depth underneath the skin surface, while effectively suppressing all noise sources.”
In the study, 48 outpatients will perform measurements in their homes on GlucoBeam prototypes, as well as on invasive glucose monitoring devices. The latter is used as reference. The study goes on for a period of 30 days for each patient. The remaining 24 patients will participate in measurements at Odense University Hospital.
“It is important for us to demonstrate the GlucoBeam®’s performance under realistic user conditions”, states RSP’s Chief Executive Officer, Jacob L. Philipsen, and continues: “It is much easier to obtain hero results under controlled hospital laboratory conditions. But the GlucoBeam® is meant as a tool to help people with diabetes improve their everyday lifestyle and therapy management. And therefore, it is under these conditions that the device must be tested.”
For more information, please contact Stefan O. Banke.